Search
for

    Learn

    5 / 5 results

      learn Clascoterone

      a novel topical treatment that inhibits DHT on androgen receptors

      learn Hydrocortisone

      a synthetic cortisol used for anti-inflammatory effects

      learn Bimatoprost

      a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp

      learn Tretinoin

      the gold standard retinoid in dermatology that's also helpful for hair regrowth alongside Minoxidil

    Research

    5 / 1000+ results

    Community Join

    5 / 35 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Verteporfin and Microneedling

      in Treatments 5 months ago
      Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.